Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles

Samuel J. Chantilis, Khaled M. Zeitoun, Snehal I. Patel, D. Alan Johns, Valerie A. Madziar, Donald D. McIntire

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Objective: To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami, FL) versus IM progesterone for luteal phase support after IVF-ET. Design: Prospective open trial with comparison to historical controls. Setting: University hospital. Patient(s): Two hundred six women undergoing IVF-ET. Intervention(s): One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval. Main Outcome Measure(s): Pregnancy and miscarriage rates, and midluteal serum progesterone levels. Result(s): Positive β-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3 ± 8.8 ng/mL versus 57.7 ± 7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval. Conclusion(s): For all age categories, positive β-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.

Original languageEnglish (US)
Pages (from-to)823-829
Number of pages7
JournalFertility and Sterility
Volume72
Issue number5
DOIs
StatePublished - Nov 1999

Fingerprint

Foams and Jellies Vaginal Creams
Corpus Luteum
Fertilization in Vitro
Pregnancy Rate
Progesterone
Oocyte Retrieval
Luteal Phase
Spontaneous Abortion
Serum
Crinone
Uterine Hemorrhage
Outcome Assessment (Health Care)

Keywords

  • Crinone
  • Embryo transfer
  • In vitro fertilization
  • Intramuscular progesterone
  • Progesterone gel

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. / Chantilis, Samuel J.; Zeitoun, Khaled M.; Patel, Snehal I.; Johns, D. Alan; Madziar, Valerie A.; McIntire, Donald D.

In: Fertility and Sterility, Vol. 72, No. 5, 11.1999, p. 823-829.

Research output: Contribution to journalArticle

Chantilis, Samuel J. ; Zeitoun, Khaled M. ; Patel, Snehal I. ; Johns, D. Alan ; Madziar, Valerie A. ; McIntire, Donald D. / Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. In: Fertility and Sterility. 1999 ; Vol. 72, No. 5. pp. 823-829.
@article{d8a326ff687b4357bd5cc9713a4d1bcb,
title = "Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles",
abstract = "Objective: To investigate the efficacy and safety of intravaginal Crinone 8{\%} (Columbia Research Laboratories, Miami, FL) versus IM progesterone for luteal phase support after IVF-ET. Design: Prospective open trial with comparison to historical controls. Setting: University hospital. Patient(s): Two hundred six women undergoing IVF-ET. Intervention(s): One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval. Main Outcome Measure(s): Pregnancy and miscarriage rates, and midluteal serum progesterone levels. Result(s): Positive β-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3 ± 8.8 ng/mL versus 57.7 ± 7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval. Conclusion(s): For all age categories, positive β-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.",
keywords = "Crinone, Embryo transfer, In vitro fertilization, Intramuscular progesterone, Progesterone gel",
author = "Chantilis, {Samuel J.} and Zeitoun, {Khaled M.} and Patel, {Snehal I.} and Johns, {D. Alan} and Madziar, {Valerie A.} and McIntire, {Donald D.}",
year = "1999",
month = "11",
doi = "10.1016/S0015-0282(99)00362-3",
language = "English (US)",
volume = "72",
pages = "823--829",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles

AU - Chantilis, Samuel J.

AU - Zeitoun, Khaled M.

AU - Patel, Snehal I.

AU - Johns, D. Alan

AU - Madziar, Valerie A.

AU - McIntire, Donald D.

PY - 1999/11

Y1 - 1999/11

N2 - Objective: To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami, FL) versus IM progesterone for luteal phase support after IVF-ET. Design: Prospective open trial with comparison to historical controls. Setting: University hospital. Patient(s): Two hundred six women undergoing IVF-ET. Intervention(s): One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval. Main Outcome Measure(s): Pregnancy and miscarriage rates, and midluteal serum progesterone levels. Result(s): Positive β-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3 ± 8.8 ng/mL versus 57.7 ± 7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval. Conclusion(s): For all age categories, positive β-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.

AB - Objective: To investigate the efficacy and safety of intravaginal Crinone 8% (Columbia Research Laboratories, Miami, FL) versus IM progesterone for luteal phase support after IVF-ET. Design: Prospective open trial with comparison to historical controls. Setting: University hospital. Patient(s): Two hundred six women undergoing IVF-ET. Intervention(s): One hundred patients received Crinone vaginal progesterone gel (90 mg once daily) and 106 patients received IM progesterone (50 mg once daily) beginning on the evening of oocyte retrieval. Main Outcome Measure(s): Pregnancy and miscarriage rates, and midluteal serum progesterone levels. Result(s): Positive β-hCG pregnancy rates, clinical pregnancy rates per transfer, and ongoing pregnancy rates were similar for the Crinone and IM progesterone groups. Women who received Crinone had higher rates of biochemical pregnancy loss but lower rates of clinical pregnancy loss (i.e., spontaneous abortion) than women who received IM progesterone. Midluteal serum progesterone concentrations were significantly higher in the IM progesterone group (94.3 ± 8.8 ng/mL versus 57.7 ± 7.4 ng/mL). Several women who received Crinone had vaginal bleeding 11-13 days after oocyte retrieval. Conclusion(s): For all age categories, positive β-hCG and ongoing pregnancy rates were similar when Crinone or IM progesterone was given for luteal phase support in IVF-ET cycles, despite lower serum progesterone concentrations and higher rates of biochemical pregnancy loss with Crinone. Although the results of this study support the use of Crinone as an acceptable alternative for luteal support after IVF-ET, differences in bleeding patterns and rates of biochemical pregnancy loss demonstrate the need for a prospective randomized study.

KW - Crinone

KW - Embryo transfer

KW - In vitro fertilization

KW - Intramuscular progesterone

KW - Progesterone gel

UR - http://www.scopus.com/inward/record.url?scp=0032702358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032702358&partnerID=8YFLogxK

U2 - 10.1016/S0015-0282(99)00362-3

DO - 10.1016/S0015-0282(99)00362-3

M3 - Article

C2 - 10560985

AN - SCOPUS:0032702358

VL - 72

SP - 823

EP - 829

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 5

ER -